• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunitybio Inc (NQ: IBRX )

    3.405 -0.115 (-3.27%)
    Streaming Delayed Price Updated: 2:33 PM EDT, Sep 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,471,943
    Open 3.520
    Bid (Size) 3.400 (79)
    Ask (Size) 3.410 (30)
    Prev. Close 3.520
    Today's Range 3.350 - 3.530
    52wk Range 1.250 - 10.53
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga

    Performance

    YTD
    -35.02%
    -35.02%
    1 Month
    -19.88%
    -19.88%
    3 Month
    -53.61%
    -53.61%
    6 Month
    -37.41%
    -37.41%
    1 Year
    +111.49%
    +111.49%

    More News

    Read More
    ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
    From ImmunityBio, Inc.
    Via Business Wire
    How Is The Market Feeling About ImmunityBio?
    Via Benzinga
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Top 3 Health Care Stocks That Are Set To Fly This Quarter
    Via Benzinga
    9 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
    From ImmunityBio, Inc.
    Via Business Wire
    IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    7 Biotech Stocks to Keep on Your Clinical Radar
    Via InvestorPlace
    3 Top Cancer Treatment Stocks to Buy Now
    Via InvestorPlace
    China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
    Via Benzinga
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why ImmunityBio Stock Is Trading Higher Thursday
    Via Benzinga
    KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
    From ImmunityBio, Inc.
    Via Business Wire
    3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
    From ImmunityBio, Inc.
    Via Business Wire
    These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024
    Via Talk Markets
    Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
    From ImmunityBio, Inc.
    Via Business Wire
    Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
    Via Talk Markets
    IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.